Nathan Caffo
Corporate Officer/Principal bij CANDEL THERAPEUTICS, INC.
Profiel
Nathan Caffo is a professional who has worked in the biotech industry.
He is currently the Chief Business Officer at Candel Therapeutics, Inc. He previously worked as the President & Chief Executive Officer at Presage Biosciences, Inc. from 2009 to 2018, and as the Chief Business Officer at ALX Oncology Holdings, Inc. from 2018 to 2020.
Mr. Caffo received his undergraduate degree from The Pennsylvania State University.
Actieve functies van Nathan Caffo
| Bedrijven | Functie | Begin |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Corporate Officer/Principal | 01-09-2020 |
Eerdere bekende functies van Nathan Caffo
| Bedrijven | Functie | Einde |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01-09-2020 |
Presage Biosciences, Inc.
 Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Algemeen Directeur | 17-07-2018 |
Opleiding van Nathan Caffo
| The Pennsylvania State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
